4-chloro-N-phenylphthalazin-1-amine | 87166-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-chloro-N-phenylphthalazin-1-amine
• 英文别名: 1-Phenylamino-4-chlorophthalazine；(4-chloro-phthalazin-1-yl)-phenyl-amine；(4-Chlor-phthalazin-1-yl)-phenyl-amin
• CAS: 87166-49-2
• 化学式: C₁₄H₁₀ClN₃
• mdl: MFCD00126032
• 分子量: 255.707
• InChiKey: DNFHFIHSDFNNJW-UHFFFAOYSA-N

物化性质

• 熔点：
  200 °C
• 沸点：
  477.5±30.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-N-phenylphthalazin-1-amine 、 苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 以78%的产率得到N,4-diphenylphthalazin-1-amine
  参考文献：
  名称：

  Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model

  摘要：

  Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.026
• 作为产物：
  描述：

  邻苯二甲酰肼 在 吡啶 、 三氯氧磷 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 生成 4-chloro-N-phenylphthalazin-1-amine
  参考文献：
  名称：

  Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model

  摘要：

  Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.026

文献信息

• Iron-Catalyzed Intermolecular C–N Cross-Coupling Reactions via Radical Activation Mechanism
  作者：Subrata Das、Andreas W. Ehlers、Sima Patra、Bas de Bruin、Buddhadeb Chattopadhyay

  DOI：10.1021/jacs.3c05627

  日期：2023.7.12

  aromatic and aliphatic azides with boronic acids under iron-catalyzed conditions. The amination follows an unprecedented metalloradical activation mechanism that is different from traditional metal-catalyzed C–N cross-coupling reactions. The scope of the reaction has been demonstrated by the employment of a large number of tetrazoles, azides, and boronic acids. Moreover, several late-stage aminations

  在铁催化条件下，使用四唑、芳香族和脂肪族叠氮化物与硼酸，发现了分子间 C-N 交叉偶联胺化的概念。胺化遵循前所未有的金属自由基活化机制，不同于传统的金属催化的 C-N 交叉偶联反应。该反应的范围已通过大量四唑、叠氮化物和硼酸的使用得到证明。此外，还展示了几种后期胺化反应和候选药物的简短合成，以供进一步的合成应用。总的来说，这种铁催化的 C-N 交叉偶联应该在药物化学、药物发现和制药工业中具有广泛的应用。
• Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells
  作者：Federico Medda、Earlphia Sells、Hui-Hua Chang、Justin Dietrich、Shashi Chappeta、Breland Smith、Vijay Gokhale、Emmanuelle J. Meuillet、Christopher Hulme

  DOI：10.1016/j.bmcl.2012.11.030

  日期：2013.1

  This Letter reports the synthesis and biological evaluation of a collection of aminophthalazines as a novel class of compounds capable of reducing production of PGE(2) in HCA-7 human adenocarcinoma cells. A total of 28 analogs were synthesized, assayed for PGE2 reduction, and selected active compounds were evaluated for inhibitory activity against COX-2 in a cell free assay. Compound 2xxiv (R-1 = H, R-2 = p-CH3O) exhibited the most potent activity in cells (EC50 = 0.02 mu M) and minimal inhibition of COX-2 activity (3% at 5 mu M). Furthermore, the anti-tumor activity of analog 2vii was analyzed in xenograft mouse models exhibiting good anti-cancer activity. (C) 2012 Elsevier Ltd. All rights reserved.
• Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase
  作者：Evgueni L. Piatnitski、Matthew A.J. Duncton、Alexander S. Kiselyov、Reeti Katoch-Rouse、Dan Sherman、Daniel L. Milligan、Chris Balagtas、Wai C. Wong、Joel Kawakami、Jacqueline F. Doody

  DOI：10.1016/j.bmcl.2005.07.064

  日期：2005.11

  A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compounds display potent VEGFR-2 inhibitory activity with an IC50 as low as 0.078 mu M in an HTRF enzymatic assay. These compounds are relatively selective against a small kinase panel. (c) 2005 Elsevier Ltd. All rights reserved.
• 157. Synthetic antimalarials. Part XXVII. Some derivatives of phthalazine, quinoxaline, and isoquinoline
  作者：Robert D. Haworth、Stanley Robinson

  DOI：10.1039/jr9480000777

  日期：——
• TAKEHXARA, XIROYUKI;TSUKAMOTO, JOSITSUGU;KAMINISI, KEHJDZI;ASAUMI, JOSIO;+
  作者：TAKEHXARA, XIROYUKI、TSUKAMOTO, JOSITSUGU、KAMINISI, KEHJDZI、ASAUMI, JOSIO、+

  DOI：——

  日期：——